Drug Trial Radar · NCT06175767
A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Sep 2027
Primary completion
Jan 2028
Study completion Mar 2028
Sponsor
- Lead sponsor
- Mthera Pharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease. Primary objective of the study is to evaluate the safety and tolerability of MT101-5 400 mg and 600 mg oral tablet total daily dose compared to Placebo in subjects with Parkinson's Disease.
Conditions
- Parkinson's Disease
Interventions
MT101-5Drug
Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Change from baseline to week 12 after the first study drug administration
- Incidence of withdrawals due to Adverse Events (AEs)Time frame: Change from baseline to week 12 after the first study drug administration
- Incidence of serious adverse events (SAEs)Time frame: Change from baseline to week 12 after the first study drug administration
- Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Change from baseline to week 12 after the first study drug administration
- Change of blood pressure (both systolic and diastolic blood pressures)Time frame: Change from baseline to week 12 after the first study drug administration
- Change of body temperatureTime frame: Change from baseline to week 12 after the first study drug administration
- Change of respiratory rateTime frame: Change from baseline to week 12 after the first study drug administration
- ECG ventricular rate (beats per minute)Time frame: Change from baseline to week 12 after the first study drug administration
- ECG PR interval (msec)Time frame: Change from baseline to week 12 after the first study drug administration
- ECG QRS interval (msec)Time frame: Change from baseline to week 12 after the first study drug administration
- ECG QT interval (msec)Time frame: Change from baseline to week 12 after the first study drug administration
- ECG QTc interval (msec)Time frame: Change from baseline to week 12 after the first study drug administration
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.